The effects of steroids during sepsis depend on dose and severity of illness: An updated meta-analysis

Clinical Microbiology and Infection

Volumn 15, Issue 4, 2009, Pages 308-318

  Minneci, P C ^a   Deans, K J ^a   Eichacker, P Q ^b   Natanson, C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Meta analysis; Review; Sepsis; Septic shock; Steroids

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYPERTENSIVE FACTOR; MEPREDNISONE; PREDNISOLONE; STEROID;

CLINICAL TRIAL; CORTICOTROPIN RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE RELEASE; LOW DRUG DOSE; META ANALYSIS; MORNING DOSAGE; MORTALITY; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLICATION; REVIEW; SECONDARY INFECTION; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 65449188293     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02752.x     Document Type: Review

References (48)

1. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-247.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
3. Angus DC, Wax RS. Epidemiology of sepsis: An update. Crit Care Med 2001; 29: S109-S116.
4. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin.III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878.
5. Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Once is not enough: clinical trials in sepsis. Intensive Care Med 2008; 34: 1955-1960.
6. Eichacker PQ, Parent C, Kalil A et al. Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205.
7. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141: 47-56.
8. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
9. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351: 47-52.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
11. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
12. Garber EK, Targoff C, Paulus HE. Glucocorticoid preparations. In: Paulus HE, Furst DE, Droomgoole SH, eds. Drugs for rheumatic diseases. New York: Churchill Livingstone, 1987; 446.
13. Breslow NE, Day NE. The analysis of case-control studies. In: Davis W, ed. Statistical methods in cancer research. Lyon, France: IARC Scientific Publications, 1980.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
16. Gonzales DA, Norsworthy KJ, Kern SJ et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: Unsupervised clustering to resolve heterogeneity. BMC Med 2007; 5: 32-44.
17. Cicarelli DD, Vieira JE, Bensenor FE. Early dexamethasone treatment for septic shock patients: A prospective randomized clinical trial. Sao Paulo Med J 2007; 125: 237-241.
18. Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-248.
19. Mussack T, Briegel J, Schelling G, Biberthaler P, Jochum M. Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med 2005; 43: 259-268.
20. Oppert M, Schindler R, Husung C et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33: 2457-2464.
21. Rinaldi S, Adembri C, Grechi S, De Gaudio AR. Low-dose hydrocortisone during severe sepsis: Effects on microalbuminuria. Crit Care Med 2006; 34: 2334-2339.
22. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
23. Tandan SM, Guleria R, Gupta N. Low dose steroids and adrenocortical insufficiency in septic shock: A double-blind randomized controlled trial from India. American Thoracic Society Meeting 2005; 2.
24. Hinshaw L, Peduzzi P, Young E et al. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987; 317: 659-665.
25. Bennett IL, Finland M, Hamburger M, Kass EH, Lepper M, Waisbren BA. The effectiveness of hydrocortisone in the management of severe infection. JAMA 1963; 183: 462-465.
26. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
27. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
28. Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-732.
29. Chawla K, Kupfer Y, Goldman I. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999; 27: A33.
30. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med 1971; 284: 1248-1250.
31. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984; 119: 537-541.
32. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-68.
33. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184: 333-341.
34. Sprung CL, Caralis PV, Marcial EH et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311: 1137-1143.
35. Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kyols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study). Clin Res 1976; 24: 258A.
36. Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6: 251-259.
37. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis. BMJ 2004; 329: 480.
38. Marik PE, Pastores SM, Annane D et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937-1949.
39. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003; 31: S94-S96.
40. Li Y, Cui X, Li X et al. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: Risk and corticosteroids in sepsis. Intensive Care Med 2008; 34: 568-577.
41. Collins S, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem 1988; 263: 9067-9070.
42. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-389.
43. Arafah BM. Hypothalamic pituitary adrenal function during critical illness: Limitations of current assessment methods. J Clin Endocrinol Metab 2006; 91: 3725-3745.
44. Bouachour G, Roy PM, Guiraud MP. The repetitive short corticotropin stimulation test in patients with septic shock. Ann Intern Med 1995; 123: 962-963.
45. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350: 1629-1638.
46. Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg 2005; 101: 1792-1798.
47. Finfer S. Corticosteroids in septic shock. N Engl J Med 2008; 358: 188-190.
48. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-873.